No 10Y consistency score yet for revenue — the year-earlier revenue was zero, negative or too small a base to compare against in 23 of the 40 quarters in the window, leaving 17 comparable quarters; at least 28 are needed.
Valuation vs own 10Y history: P/S 3.0x · 10Y median 20.4x · 7th percentile · as of Oct 5, 2026
Annualized revenue (TTM) · by quarter, last 40
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T13:21:15.622Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Quote observation: 2026-10-06T13:21:15.622Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Unrounded diluted TTM EPS / FMP quote price × 100. Quote observation: 2026-10-06T13:21:15.622Z. Latest historical point 2026-10-05.
Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Quote observation: 2026-10-06T13:21:15.622Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Compugen Ltd. (CGEN) stock was $2.31 as of Oct 5, 2026, 4:00 PM EDT, unchanged from the previous close.
Longer view (total return, dividends reinvested): past 12 months +41.5% · 3-year avg +37.5%/yr · 5-year avg -18.4%/yr
Compugen Ltd., an Israeli-based company established in 1993 and headquartered in Holon, is a clinical-stage enterprise focused on the discovery, development, and commercialization of therapeutic and product candidates. Its operations extend across Israel, the United States, and Europe.
Biotechnology · Holon, TA
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Next Earnings Date
Nov 9, 2026
34 days away
EPS Estimate
-0.08
Revenue Est.
$1.28M
Last Quarter Results
EPS
$-0.07
vs Estimate
$-0.09
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1CGEN | $218.42M | $2.31 | +0.00% | +41.48% | -18.39% | -9.42% | N/A |
| 2ALEC | $220.94M | $1.99 | +9.94% | -39.91% | -39.17% | N/A | vs CGEN |
| 3KROS | $228.41M | $11.52 | +1.41% | -27.62% | -21.98% | N/A | vs CGEN |
| 4ETRA | $206.61M | $9.74 | -6.08% | N/A | N/A | N/A | vs CGEN |
| 5ANTX | $202.05M | $5.61 | -1.75% | +328.54% | N/A | N/A | vs CGEN |
| 6BDSX | $236.56M | $29.06 | +4.83% | +273.09% | -28.49% | N/A | vs CGEN |
$2.60M
vs Estimate
$1.28M
Consensus Rating
Based on 5 analysts
Average Price Target
$4.60
+99.1% upside
Low
$4.00
Current
$2.31
High
$6.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.10 | $-0.08 | $-0.06 | 3 |
| Quarter ending Dec 2026 | $-0.09 | $-0.05 | $0.02 | 3 |
| Quarter ending Mar 2027 | $-0.16 | $-0.09 | $-0.01 | 1 |
| Quarter ending Jun 2027 | $-0.16 | $-0.08 | $-0.01 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-0.35 | $-0.28 | $-0.19 | 3 |
| FY 2027 | $-0.57 | $-0.28 | $0.15 | 3 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $1.19M | $1.28M | $1.38M | 3 |
| Quarter ending Dec 2026 | $1.63M | $5.02M | $8.42M | 3 |
| Quarter ending Mar 2027 | $151515.00 | $466667.00 | $781818.00 | 1 |
| Quarter ending Jun 2027 | $151515.00 | $466667.00 | $781818.00 | 1 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $4.17M | $10.20M | $17.95M | 3 |
| FY 2027 | $9.83M | $16.05M | $22.26M | 3 |
